Advancing Immunotherapy Vaccines for Patients with RAS-Mutated Cancers

- Targovax is a Norwegian-based global biotechnology company developing RAS-targeted immunotherapy vaccines.
- Lead product TG01 has demonstrated early immune responses in resected pancreatic cancer patients.
- Targovax’s product candidates are targeted at a wide range of RAS-mutated cancers where treatment resistance is high and currently available therapies are limited or ineffective.

![Diagram of the immunotherapy process](image)

1. RAS-mutated peptides and the immune-stimulator molgramostim (GM-CSF) are injected into the skin. Dendritic cells of the immune system take up the RAS-mutated peptides and are activated by molgramostim.
2. Once activated, the dendritic cells migrate into the lymph nodes where they present the RAS-mutated peptides to immune T cells. Subsets of T cells learn to recognize these RAS-mutated peptides.
3. Activated T cells enter the circulation and search throughout the body for RAS-mutated cancer cells.
4. As soon as the activated T cells find RAS-mutated cancer cells, the T cells proliferate and trigger the immunological killing of cancer cells.
5. RAS-mutated cancer cells are then destroyed by activated T cells.

<table>
<thead>
<tr>
<th>Product</th>
<th>Target Indication</th>
<th>Discovery &amp; lead development</th>
<th>Pre-clinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>TG01</td>
<td>Pancreatic cancer</td>
<td>(&gt;85% RAS mutations)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TG02</td>
<td>Colorectal cancer</td>
<td>(&gt;40% RAS mutations)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TG03</td>
<td>Currently under evaluation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FOR FURTHER INFORMATION PLEASE CONTACT:
Targovax AS, Vollsveien 6, 1366 Lysaker, Norway Phone +47 21 39 88 10, contact@targovax.com